Fedora Pharmaceuticals Inc.
U.S. drug resistance causes +63,000 deaths and costs +$20 billion annually! Fedora's drug reverses resistance. Annual market is +$1 billion.
- Stage Concept Only
- Industry Biotechnology
- Location Edmonton, AB, Canada
- Currency CAD
Company Summary
Fedora's team have made an important discovery believed to be the first of its kind: A single product that potentiates the activity of antibiotics such as penicillin and restores activity. There is no such drug on the market or in development that possesses the same spectrum as Fedora's. A near virtual team of world recognized industry experts will advance the program to commercialization in as short a time as possible.
Team
-
Christopher George MicetichFounder/President & CEO
-
Dr. Thomas ParrChief Scientific Officer
-
Dr. Karen BushS.A.B. Member
-
Dr. Eric GordonS.A.B. Member
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.